Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage Antiretroviral Therapies for HIV-Infected Individuals Failing Nelfinavir
NCT00000918Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ritonavir, saquinavir, efavirenz, indinavir and amprenavir in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Plasma HIV RNA Concentration at 16 weeks and Safety and Tolerability at 16 weeks. Status: completed.
02
Drugs
ritonavirsaquinavirefavirenzindinaviramprenavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000918.